Alveofact 50mg Injection

Alveofact 50mg Injection contains phospholipid fraction from bovine lung as its active component. It is used in the treatment of respiratory distress syndrome (RDS) in premature infants. RDS occurs when the lungs do not produce sufficient surfactant, a substance necessary for maintaining lung elasticity and preventing alveolar collapse. In severe pneumonia, particularly in premature infants or newborns with compromised lung function, this medication may be used to support breathing. This medication may also assist with lung function in infants who pass stool (meconium) while in the womb and inhale it into their lungs before or during delivery, resulting in breathing difficulties.

Alveofact 50mg Injection is contraindicated in individuals with known severe allergies to its components. Active or severe infections may represent a contraindication to this medication due to potential risk of worsening the infection or complicating treatment. It may not be recommended for infants above a certain gestational age or weight threshold, as their lung maturity may not benefit from this intervention. In patients with severe bleeding disorders or increased bleeding risk, administration may pose a risk of pulmonary haemorrhage or exacerbate bleeding issues, and healthcare provider consultation is necessary before administration. Alveofact 50mg Injection is primarily used in neonatal care and is not typically administered to older adults.

Neonatal respiratory distress syndrome (RDS) Meconium aspiration syndrome Pneumonia Acute respiratory distress syndrome (ARDS) Lung surfactant deficiency

Alveofact 50mg Injection reduces surface tension at the air-liquid interface in the lungs' alveoli, preventing collapse during exhalation and ensuring these tiny air sacs stay open for gas exchange. Composed of lipids and proteins, it enhances lung compliance, making breathing easier. In conditions like respiratory distress syndrome (RDS) or surfactant deficiencies, surfactant replacement therapy supplements or replaces insufficient surfactant, improving lung function and preventing breathing complications.

Alveofact 50mg Injection should be used only when there is enough facility for ventilation and monitoring. This medicine should be administered via the intra-tracheal route. Your baby’s physician and nurse should constantly monitor to ensure that the right amount of oxygen is given. Dosing shall be stopped by the physician in case of a slow heartbeat or reduced oxygen in circulation and resumed only after the condition is stable.

Alveofact 50mg Injection causes some side effects like all medications, although not everyone will experience them. Serious: Airway blockage Infection Allergic reactions Pulmonary hemorrhage Common: Transient oxygen desaturation Changes in heart rate Breathing difficulties

Ensure Alveofact 50mg Injection administration is conducted by trained healthcare professionals familiar with the procedure to minimize the risk of complications. Have proper ventilatory support available before and during administration to manage potential changes in oxygen levels or breathing difficulties. Continuously monitor your vital signs, oxygen levels, and respiratory status during and after administration to promptly address any adverse reactions or complications. Adhere strictly to aseptic techniques during administration to minimize the risk of infection. Ensure proper patient positioning to facilitate the administration process and minimize the risk of aspiration or airway obstruction. Conduct a thorough risk assessment, especially in cases of underlying lung conditions or compromised respiratory function, to determine surfactant therapy's potential benefits and risks.